Share：
Share this content in WeChat
X
[Chinese] [PDF] 11 1
• Review •
Advances in mpMRI and radiomics for differentiating granulomatous mastitis from non-mass-like breast cancer
CHEN Tiantian  ZHAO Haifeng  ZHANG Xuan  WANG Xiaohuan  LI Ruitong  WANG Xiaodong  ZHANG Hao 

Cite this article as: CHEN T T, ZHAO H F, ZHANG X, et al. Advances in mpMRI and radiomics for differentiating granulomatous mastitis from non-mass-like breast cancer[J]. Chin J Magn Reson Imaging, 2025, 16(10): 171-176. DOI:10.12015/issn.1674-8034.2025.10.027.


[Abstract] Granulomatous Mastitis (GM) is a relatively rare benign inflammatory breast disease. Most lesions present as non-mass enhancement, resulting in significant overlap with non-mass breast cancer (NMBC) in both imaging and clinical manifestations. This makes non-invasive differentiation between GM and NMBC clinically challenging.Multiparametric MRI (mpMRI) addresses this challenge by integrating information from multiple MRI sequences, enabling multidimensional quantification of dynamic lesion progression and providing critical insights into lesion characteristics. Radiomics further enhances diagnostic precision by extracting high-throughput features capable of capturing subtle patterns imperceptible to the human eye.This article reviews recent advances in mpMRI and radiomics for distinguishing GM from NMBC,and analyzes the current limitations of these studies and identifies potential future research directions, with the aim of reducing unnecessary invasive procedures, guiding early clinical decision-making, and improving patients' quality of life and long-term outcomes.
[Keywords] multiparametric magnetic resonance imaging；radiomics；granulomatous mastitis；non-mass breast cancer

CHEN Tiantian1, 2   ZHAO Haifeng1, 2   ZHANG Xuan1, 2   WANG Xiaohuan1, 2   LI Ruitong1, 2   WANG Xiaodong1, 2   ZHANG Hao2*  

1 The First Clinical Medical College of Lanzhou University , Lanzhou 730000, China

2 Department of Radiology, the First Hospital of Lanzhou University/Gansu Intelligent Imaging Medical Engineering Research, Lanzhou 730000, China

Corresponding author: ZHANG H, E-mail: zhanghao@lzu.edu.cn

Conflicts of interest   None.

Received  2025-07-29
Accepted  2025-09-27
DOI: 10.12015/issn.1674-8034.2025.10.027
Cite this article as: CHEN T T, ZHAO H F, ZHANG X, et al. Advances in mpMRI and radiomics for differentiating granulomatous mastitis from non-mass-like breast cancer[J]. Chin J Magn Reson Imaging, 2025, 16(10): 171-176. DOI:10.12015/issn.1674-8034.2025.10.027.

[1]
LOU Y, XU H, LU Z X, et al. Immune regulation: a new strategy for traditional Chinese medicine-based treatment of granulomatous lobular mastitis[J/OL]. Front Immunol, 2024, 15: 1494155 [2025-07-28]. https://pubmed.ncbi.nlm.nih.gov/39544943/. DOI: 10.3389/fimmu.2024.1494155.
[2]
TAO J, LIU Y, YANG J R, et al. MRI imaging feature analysis of granulomatous mastitis[J]. J Clin Radiol, 2021, 40(10): 1878-1883. DOI: 10.13437/j.cnki.jcr.2021.10.009.
[3]
SHANBHAG N M, AMERI M A, SHANBHAG S N, et al. Diagnostic challenges and insights into granulomatous mastitis: a systematic review[J/OL]. Cureus, 2024, 16(12): e75733 [2025-07-28]. https://pubmed.ncbi.nlm.nih.gov/39816317/. DOI: 10.7759/cureus.75733.
[4]
YIN Y L, LIU X H, MENG Q J, et al. Idiopathic granulomatous mastitis: etiology, clinical manifestation, diagnosis and treatment[J]. J Invest Surg, 2022, 35(3): 709-720. DOI: 10.1080/08941939.2021.1894516.
[5]
WANG X L, HE X J, LIU J Z, et al. Immune pathogenesis of idiopathic granulomatous mastitis: from etiology toward therapeutic approaches[J/OL]. Front Immunol, 2024, 15: 1295759 [2025-07-28]. https://pubmed.ncbi.nlm.nih.gov/38529282/. DOI: 10.3389/fimmu.2024.1295759.
[6]
WILSON B F, CHIN J C. Idiopathic granulomatous lobular mastitis: a mimicker of inflammatory breast cancer[J]. Fed Pract, 2023, 40(9): 325-328. DOI: 10.12788/fp.0408.
[7]
ONG S S, SIM J X Y, CHAN C W, et al. Current approaches to diagnosing and treating idiopathic granulomatous mastitis: a summary from in-depth clinician interviews[J/OL]. Heliyon, 2024, 10(19): e38345 [2025-07-28]. https://pubmed.ncbi.nlm.nih.gov/39386822/. DOI: 10.1016/j.heliyon.2024.e38345.
[8]
KUANG J, HUANG S T, HUANG X H, et al. Interpretable machine learning model for predicting preoperative histological grade of invasive breast cancer based on high resolution delay period of magnetic resonance imaging[J]. Chin J Magn Reson Imag, 2025, 16(5): 164-169, 216. DOI: 10.12015/issn.1674-8034.2025.05.025.
[9]
KUBOTA K, MORI M, FUJIOKA T, et al. Magnetic resonance imaging diagnosis of non-mass enhancement of the breast[J]. J Med Ultrason (2001), 2023, 50(3): 361-366. DOI: 10.1007/s10396-023-01290-2.
[10]
LIU X Y, CAO M Q. Survival of female patients with breast cancer in a hospital-based cancer registry: a report of 8170 cases[J]. Pract J Cancer, 2022, 37(4): 659-663. DOI: 10.3969/j.issn.1001-5930.2022.04.037.
[11]
ASLAN H, POURBAGHER A, COLAKOGLU T. Idiopathic granulomatous mastitis: magnetic resonance imaging findings with diffusion MRI[J]. Acta Radiol, 2016, 57(7): 796-801. DOI: 10.1177/0284185115609804.
[12]
YIN L, WEI X, ZHANG Q, et al. Multimodal ultrasound assessment of mass and non-mass enhancements by MRI: Diagnostic accuracy in idiopathic granulomatous mastitis and breast cancer[J/OL]. Breast, 2024, 78: 103797 [2025-07-28]. https://pubmed.ncbi.nlm.nih.gov/39418768/. DOI: 10.1016/j.breast.2024.103797.
[13]
WANG H, VAN DER VELDEN B H M, RAGUSI M A A, et al. Toward computer-assisted triaging of magnetic resonance imaging-guided biopsy in preoperative breast cancer patients[J]. Invest Radiol, 2021, 56(7): 442-449. DOI: 10.1097/RLI.0000000000000759.
[14]
MARINO M A, AVENDANO D, SEVILIMEDU V, et al. Limited value of multiparametric MRI with dynamic contrast-enhanced and diffusion-weighted imaging in non-mass enhancing breast tumors[J/OL]. Eur J Radiol, 2022, 156: 110523 [2025-07-28]. https://pubmed.ncbi.nlm.nih.gov/36122521/. DOI: 10.1016/j.ejrad.2022.110523.
[15]
YANG Y P, LIU J, SHU J. Comparative analysis of apparent diffusion coefficient (ADC) metrics for the differential diagnosis of breast mass lesions[J/OL]. BMC Med Imaging, 2025, 25(1): 117 [2025-07-28]. https://pubmed.ncbi.nlm.nih.gov/40217169/. DOI: 10.1186/s12880-025-01654-9.
[16]
DAIMIEL NARANJO I, GIBBS P, REINER J S, et al. Breast lesion classification with multiparametric breast MRI using radiomics and machine learning: a comparison with radiologists' performance[J/OL]. Cancers (Basel), 2022, 14(7): 1743 [2025-07-28]. https://pubmed.ncbi.nlm.nih.gov/35406514/. DOI: 10.3390/cancers14071743.
[17]
YUAN Q Q, XIAO S Y, FAROUK O, et al. Management of granulomatous lobular mastitis: an international multidisciplinary consensus (2021 edition)[J/OL]. Mil Med Res, 2022, 9(1): 20 [2025-07-28]. https://pubmed.ncbi.nlm.nih.gov/35473758/. DOI: 10.1186/s40779-022-00380-5.
[18]
SOYLU BOY F N, ESEN ICTEN G, KAYADIBI Y, et al. Idiopathic granulomatous mastitis or breast cancer? a comparative MRI study in patients presenting with non-mass enhancement[J/OL]. Diagnostics (Basel), 2023, 13(8): 1475 [2025-07-28]. https://pubmed.ncbi.nlm.nih.gov/37189576/. DOI: 10.3390/diagnostics13081475.
[19]
ZHOU H Y, LI H, WANG S L, et al. Clinical analysis of misdiagnosis of granulomatous lobular mastitis[J]. Clin Misdiagnosis Mistherapy, 2024, 37(6): 10-13. DOI: 10.3969/j.issn.1002-3429.2024.06.003.
[20]
GAO L, WANG X P, LI B. Analysis of DCE-MRI and DWI in the differential diagnosis of breast cancer and granulomatous mastitis[J]. Chin J CT MRI, 2025, 23(5): 95-98. DOI: 10.3969/j.issn.1672-5131.2025.05.028.
[21]
DUAN B, WANG X J, KONG L. 3.0 mechanism of TMR dynamic enhancement curve combined with ADC in the differential diagnosis of benign and malignant lesions of the breast[J]. J Rare Uncommon Dis, 2023, 30(8): 51-52. DOI: 10.3969/j.issn.1009-3257.2023.08.021.
[22]
LI J Y, ZHENG H, WANG Y F, et al. Diagnosis value of magnetic resonance imaging for non mass like granulomatous lobular mastitis and breast cancer[J]. Med J Wuhan Univ, 2021, 42(1): 88-91. DOI: 10.14188/j.1671-8852.2020.0055.
[23]
ZHAO Y Q, CHEN Y Y, ZHAO L. Evaluation of X-ray molybdenum target combined with MRI-DWI for non-mass breast cancer[J]. J Med Imag, 2024, 34(6): 51-54. DOI: 10.3760/cma.j.issn.1006-9011.2024.06.011.
[24]
ZHANG Z X, WANG Y A, FANG Y, et al. The value of mastitis by multimodal imaging in diagnosis of granulomatrus mastitis[J]. J Med Imag, 2023, 33(7): 1176-1180. DOI: 10.3760/cma.j.issn.1006-9011(2023)07.1176.05.
[25]
ZHOU G P, LI J M, LI J Z. Diagnostic value of ultrasound SWE technique combined with MRI for non-mass breast cancer[J]. Clin Misdiagnosis Mistherapy, 2024, 37(11): 34-38. DOI: 10.3969/j.issn.1002-3429.2024.11.007.
[26]
LIU P, ZHANG W, LI C Z, et al. Imaging features and differential diagnosis of granulomatous mastitis and breast cancer with non-mass-like enhancement on MRI[J]. Chin Imag J Integr Tradit West Med, 2024, 22(4): 418-423. DOI: 10.3969/j.issn.1672-0512.2024.04.010.
[27]
DONG X Y. The application value of MRI in non-bulky breast cancer and granulomatous mastitis[D]. Urumqi: Xinjiang Medical University, 2020. DOI: 10.27433/d.cnki.gxyku.2020.000574.
[28]
QU N, LUO Y H, YU T. Differentiation between clinically noninflammatory granulomatous lobular mastitis and noncalcified ductal carcinoma in situ using dynamic contrast-enhanced magnetic resonance imaging[J]. Breast Care (Basel), 2020, 15(6): 619-627. DOI: 10.1159/000506068.
[29]
GUO N, LI J, ZHANG R Z, et al. Diagnostic value of MRI in non-lactation mastitis lesions[J]. Chin J Magn Reson Imag, 2019, 10(1): 31-36. DOI: 10.12015/issn.1674-8034.2019.01.006.
[30]
JONES L I, KLIMCZAK K, GEACH R. Breast MRI: an illustration of benign findings[J/OL]. Br J Radiol, 2023, 96(1142): 20220280 [2025-07-28]. https://academic.oup.com/bjr/article/96/1142/20220280/7468187. DOI: 10.1259/bjr.20220280.
[31]
DUAN X L, CHEN S M, ZHANG P. The value of dynamic contrast-enhanced MRI in differentiating non-masslike enhancement breast cancer from granulomatous mastitis[J]. Chin J CT MRI, 2025, 23(1): 103-105. DOI: 10.3969/j.issn.1672-5131.2025.01.035.
[32]
WU L H, YANG W, ZHOU X P, et al. Clinical features, mammography and MRI manifestations for differentiating non-mass breast cancer and mastitis[J]. Chin J Med Imag Technol, 2023, 39(11): 1653-1658. DOI: 10.13929/j.issn.1003-3289.2023.11.013.
[33]
WANG C H. Diagnostic efficacy of dynamic contrast-enhanced MRI combined with diffusion-weighted imaging in non-mass breast cancer and granulomatous mastitis[J]. J Imag Res Med Appl, 2023, 7(9): 87-89. DOI: 10.3969/j.issn.2096-3807.2023.09.028.
[34]
GAUTIER N, LALONDE L, TRAN-THANH D, et al. Chronic granulomatous mastitis: Imaging, pathology and management[J/OL]. Eur J Radiol, 2013, 82(4): e165-75 [2025-07-28]. https://pubmed.ncbi.nlm.nih.gov/23200627/. DOI: 10.1016/j.ejrad.2012.11.010.
[35]
WANG L J, WANG D B, FEI X C, et al. MRI findings of inflammatory breast diseases with pathologic correlation in non-lactating woman[J]. Chin J Radiol, 2014, 48(10): 836-840. DOI: 10.3760/cma.j.issn.1005-1201.2014.10.011.
[36]
LI Z Y, LIU J Y, SHENG L J. The value of MRI perfusion imaging in differential diagnosis of granulomatous mastitis and non-mass breast cancer[J]. J Med Imag, 2018, 28(3): 396-399. DOI: 10.3760/cma.j.issn.1006-9011(2018)03-0396-04.
[37]
ZHOU Y, ZHANG X, WEN Y, et al. Value of MRI perfusion imaging combined with serum SAA and TFF1 detection in differentiating granulomatous mastitis from non-mass breast cancer[J]. J Mol Diagn Ther, 2025, 17(1): 88-91. DOI: 10.19930/j.cnki.jmdt.2025.01.035.
[38]
CHEN Y, WU X Y, ZHANG M, et al. Value of MR pharmacokinetic perfusion scan in differential diagnosis between idiopathic granulomatous mastitis and invasive ductal carcinoma appearing as segmental distribution enhancement[J]. Chin J Magn Reson Imag, 2024, 15(3): 177-182. DOI: 10.12015/issn.1674-8034.2024.03.028.
[39]
LI C Z, WANG W S, REN H, et al. MR imaging comparative study of granulomatous mastitis and invasive breast cancer[J]. J Med Imag, 2023, 33(10): 1800-1803. DOI: 10.3969/j.issn.1006-79011(2023)10-1800-04.
[40]
ZHAN R T, CHEN B, WANG X D, et al. The value of dynamic contrast-enhanced MRI combined with DWI in differentiating non-mass breast cancer from granulomatous mastitis[J]. Chin J Magn Reson Imag, 2018, 9(12): 948-952. DOI: 10.12015/issn.1674-8034.2018.12.012.
[41]
SHI Y F, CAO Z H, LIU Y W, et al. Differentiation value of dynamic contrast-enhanced MRI, DWI and ADC values in granulomatous lobular mastitis from breast cancer[J]. Mod Med Imageology, 2022, 31(7): 1189-1193. DOI: 10.3969/j.issn.1006-7035.2022.07.001.
[42]
JIN G W, AN N Y, JACOBS M A, et al. The role of parallel diffusion-weighted imaging and apparent diffusion coefficient (ADC) map values for evaluating breast lesions: preliminary results[J]. Acad Radiol, 2010, 17(4): 456-463. DOI: 10.1016/j.acra.2009.12.004.
[43]
EGHTEDARI M, MA J F, FOX P, et al. Effects of magnetic field strength and b value on the sensitivity and specificity of quantitative breast diffusion-weighted MRI[J]. Quant Imaging Med Surg, 2016, 6(4): 374-380. DOI: 10.21037/qims.2016.07.06.
[44]
ZHANG T. A study on the differentiation of non-lactating mastitis and non-bulky breast cancer based on multimodal MRI[D]. Chengde: Chengde Medical College, 2023. DOI: 10.27691/d.cnki.gcdyx.2023.000059.
[45]
LIU Y L, JIA X X, ZHAO J Q, et al. A machine learning-based unenhanced radiomics approach to distinguishing between benign and malignant breast lesions using T2-weighted and diffusion-weighted MRI[J]. J Magn Reson Imaging, 2024, 60(2): 600-612. DOI: 10.1002/jmri.29111.
[46]
FENG Y H. Value of DWI and ADC combined enhancement in the differential diagnosis of non-mass breast cancer and inflammatory lesions[J]. World J Complex Med, 2023, 9(6): 38-41. DOI: 10.11966/j.issn.2095-994X.2023.09.06.11.
[47]
PARTRIDGE S C, SINGER L, SUN R, et al. Diffusion-weighted MRI: influence of intravoxel fat signal and breast density on breast tumor conspicuity and apparent diffusion coefficient measurements[J]. Magn Reson Imaging, 2011, 29(9): 1215-1221. DOI: 10.1016/j.mri.2011.07.024.
[48]
PERIĆ I, BRKLJAČIĆ B, TADIĆ T D, et al. DWI in the differentiation of malignant and benign breast lesions presenting with non-mass enhancement on CE-MRI[J/OL]. Cancers (Basel), 2024, 17(1): 31 [2025-07-28]. https://pubmed.ncbi.nlm.nih.gov/39796662/. DOI: 10.3390/cancers17010031.
[49]
XU H, YANG A, HU Y T, et al. Value of radiomics model based on DCE-MRI combined with blood cell parameters in differentiating Luminal and Non-Luminal breast cancer[J]. Chin J Magn Reson Imag, 2025, 16(4): 33-40, 150. DOI: 10.12015/issn.1674-8034.2025.04.006.
[50]
CHEN T, SU X J, WANG L, et al. Prediction of neoadjuvant chemotherapy for breast cancer based on ADC radiomics[J]. J Pract Med Imag, 2025, 26(4): 250-255. DOI: 10.16106/j.cnki.cn14-1281/r.2025.04.002.
[51]
LV S Y, ZHAO Q F, WANG X Y, et al. The value of radiomics in discriminating granulomatous lobular mastitis from invasive breast cancer in non-mass-like enhancing lesions[J]. J Clin Radiol, 2025, 44(2): 253-258. DOI: 10.13437/j.cnki.jcr.2025.02.003.
[52]
KAYADIBI Y, SARACOGLU M S, KURT S A, et al. Differentiation of malignancy and idiopathic granulomatous mastitis presenting as non-mass lesions on MRI: radiological, clinical, radiomics, and clinical-radiomics models[J]. Acad Radiol, 2024, 31(9): 3511-3523. DOI: 10.1016/j.acra.2024.03.025.
[53]
XING P Y, CHEN L G, YANG Q S, et al. Differentiating prostate cancer from benign prostatic hyperplasia using whole-lesion histogram and texture analysis of diffusion- and T2-weighted imaging[J/OL]. Cancer Imag, 2021, 21(1): 54 [2025-07-28]. https://cancerimagingjournal.biomedcentral.com/articles/10.1186/s40644-021-00423-5. DOI: 10.1186/s40644-021-00423-5.
[54]
ZHAO Q F, XIE T W, FU C X, et al. Differentiation between idiopathic granulomatous mastitis and invasive breast carcinoma, both presenting with non-mass enhancement without rim-enhanced masses: The value of whole-lesion histogram and texture analysis using apparent diffusion coefficient[J/OL]. Eur J Radiol, 2020, 123: 108782 [2025-07-28]. https://pubmed.ncbi.nlm.nih.gov/31864142/. DOI: 10.1016/j.ejrad.2019.108782.

PREV Advances in the application of CMR based radiomics in cardiac diseases
NEXT Research progress of MRI-based habitat analysis in the clinical diagnosis and treatment of breast cancer
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn